GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?
- Design
- Narrative review · Intermediate outcome
- Match to healthy normal-weight adults aged 55–75
- Population unclearUNKNOWN: a narrative review defined by drug and side effect rather than by a population; the abstract gives no age, BMI or diabetes data for the people in the studies it covers.
- Could weight loss explain it?
- LikelyThe authors state that telogen effluvium is driven mainly by the size and speed of weight loss rather than drug toxicity, and that weight reduction above 10% predicts hair loss; this is the reviewers' synthesis, not a mediation analysis.
- Study tier
- Not ratedNOT_RATED: a narrative review with no new primary data and no pooled estimate.
- Assessment
- Version 2 · Two reviewers differed; settled by a recorded ruling · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
This narrative review looks at hair loss with semaglutide, tirzepatide and retatrutide. Reported rates range from 3 to 7% in controlled trials to over 70% in real-world cohorts, and drug-safety databases show signals for semaglutide and tirzepatide. The authors say most cases are a temporary shedding driven by fast, large weight loss, with women and people losing more than 10% of body weight most affected, while some other hair conditions were reported to improve. As a narrative review of mixed sources, it cannot show that the drugs cause hair loss.
01Findings
What the study reported
- Drugs
- Semaglutide, Tirzepatide, Retatrutide
- Comparator
- not reported in abstract
- Primary outcome
- Prevalence, mechanisms and clinical course of hair loss with incretin-based therapies
- Effect
- Hair loss prevalence from 3 to 7% in controlled trials to over 70% in real-world cohorts; inconsistent but significant pharmacovigilance signals for semaglutide and tirzepatide; paradoxical improvements in androgenetic and scarring alopecias reported.
- 95% confidence interval
- Not extracted
- Follow-up
- Not stated
- Adverse events
- Hair loss, mainly telogen effluvium, which the authors attribute chiefly to the size and speed of weight loss; pharmacovigilance reporting odds ratios indicate a drug-associated risk for semaglutide and tirzepatide; female sex and weight reduction above 10% were the strongest predictors; described as mostly transient and reversible.
- Limitations
- Narrative review of a single database (PubMed/MEDLINE) with no pooled estimate; prevalence figures differ widely between trials and real-world cohorts.
Who was studied
- Obesity status
- not reported in abstract
- Diabetes status
- not reported in abstract
- Cvd status
- not reported in abstract
- Ckd status
- not reported in abstract
- Baseline condition
- not reported in abstract
Study quality details
- Study design
- Narrative review
- Sample size
- not extracted
- Randomization
- n/a
- Blinding
- n/a
- Comparator
- not reported in abstract
- Follow up duration
- not stated
- Outcome type
- intermediate
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- UNKNOWN
- Statistical precision
- no CI reported
- Risk of bias
- not assessed
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- The authors declare no conflicts of interest.
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
[OBJECTIVE] Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual/triple agonists, have revolutionized the management of obesity and type 2 diabetes. However, hair loss has emerged as an adverse event in clinical practice. This review synthesizes the evidence on the prevalence, mechanistic pathways, and clinical course of hair loss associated with semaglutide, tirzepatide, and retatrutide. [METHODS] A narrative review was conducted using the PubMed/MEDLINE database. Data were integrated from clinical trials, real-world observational studies, and pharmacovigilance databases to evaluate the oncological and dermatological implications of these therapies. [RESULTS] There is a discrepancy in hair loss prevalence, ranging from 3 to 7% in controlled trials to over 70% in real-world cohorts. Telogen effluvium (TE) is the predominant phenotype, driven primarily by the magnitude and velocity of weight loss rather than drug toxicity. Newer agents like tirzepatide demonstrate stronger associations with hair shedding compared to older GLP-1 RAs. Pharmacovigilance data show inconsistent but significant signals for semaglutide and tirzepatide, with reporting odds ratios indicating a drug-associated risk. Conversely, paradoxical improvements in androgenetic alopecia and inflammatory scarring alopecias have been reported, likely mediated by metabolic normalization and anti-inflammatory effects. Female sex and significant weight reduction (> 10%) were the most robust predictors of hair loss. [CONCLUSION] Hair loss associated with incretin-based therapies is a biologically complex, threshold-dependent phenomenon reflecting systemic metabolic reprogramming. While predominantly transient and reversible, its psychological impact can compromise treatment adherence. Clinicians should provide proactive counseling, emphasizing the self-limiting nature of TE in this context while monitoring for diverse follicular responses.